Search
for
Sort by
Research 91–120 of 1000+
- The genetic basis of dermatophytosis skin infection susceptibility
- Patched-assoziierte Tumoren: Modifikatorgene und Pathogenese
- A plain language summary of quality of life with sacituzumab govitecan treatment in the TROPiCS-02 study in participants with breast cancer (HR-positive/HER2-negative)
- Non‐biologic immunosuppressive drugs for inflammatory and autoimmune skin diseases
- Azithromycin and Roxithromycin define a new family of “senolytic” drugs that target senescent human fibroblasts
- Appropriateness of oral drugs for long-term treatment of lower urinary tract symptoms in older persons: results of a systematic literature review and international consensus validation process (LUTS-FORTA 2014)
- A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata
- “‘You lose your hair, what’s the big deal?’ I was so embarrassed, I was so self-conscious, I was so depressed:” a qualitative interview study to understand the psychosocial burden of alopecia areata
- Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: A pooled analysis
- Anticancer effects of metformin on neuroendocrine tumor cells in vitro
- New developments in the molecular treatment of ichthyosis: review of the literature
- Major Differences in Expression of Inflammatory Pathways in Skin from Different Body Sites of Healthy Individuals
- Scalp biomarkers during dupilumab treatment support Th2 pathway pathogenicity in alopecia areata
- Trastuzumab Induced Chemobrain, Atorvastatin Rescued Chemobrain with Enhanced Anticancer Effect and without Hair Loss-Side Effect
- A Systemic Review on Topical Marketed Formulations, Natural Products, and Oral Supplements to Prevent Androgenic Alopecia: A Review
- Proteolysis‐Targeting Chimera (PROTAC): Current Applications and Future Directions
- Symptomatic hypercalcemia and scarring alopecia as presenting features of sarcoidosis
- A Phase 1, Open‐Label Study of the Pharmacokinetics of Ritlecitinib in Children Aged 6–12 Years With Alopecia Areata
- Advancing Design Strategy of PROTACs for Cancer Therapy
- A clinician’s guide to pediatric and adolescent alopecia areata treatments
- Setipiprant for Androgenetic Alopecia in Males: Results from a Randomized, Double-Blind, Placebo-Controlled Phase 2a Trial
- Alopecia areata: A clinical review of the changing landscape with Janus kinase inhibitors
- Abstracts from the 55th European Society of Human Genetics (ESHG) Conference: e-Posters
- Somatotropin Penetration Testing from Formulations Applied Topically to the Skin
- Ancient botanicals and the skin: Defining dermatologic ethnophytoconvergence as a translational framework for pharmacognosy
- Alopecia areata exhibits cutaneous and systemic OX40 activation across atopic backgrounds
- Repurposing DPP4-Inhibition to Improve Hair Follicle Activation and Regeneration
- FDA approves Pfizer's JAK inhibitor for adolescents with alopecia areata hair loss
- NDA Submission of Vepdegestrant (ARV-471) to U.S. FDA: The Beginning of a New Era of PROTAC Degraders
- Letter in Reply: Alopecia areata after SARS-CoV-2 vaccination